Something remarkable has happened in the Indian pharmaceutical market. Mounjaro, Eli Lilly’s tirzepatide, is now India’s No. 1 pharmaceutical brand by monthly value, according to Pharmarack’s July 2026 Pharma Monitor. At approximately Rs 109.8 crore for July, Mounjaro has overtaken some of the most deeply entrenched brands in Indian medicine, including Augmentin, Glycomet GP, Zerodol…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
